New drug review
Juvmo
Review section
| Field | Value |
|---|---|
| Drug | Juvmo (tavapadon) |
| Indication reviewed | Parkinson's disease |
| Therapeutic category | Non-ergot dopamine agonists (selective dopamine D1/D5 receptor partial agonist) |
| Manufacturer | AbbVie |
| Regulatory status | Approved September 25, 2026 |
| Data as of | September 27, 2026 |
| Review status | Draft for pharmacy and therapeutics committee review |
Indications
Table 1. FDA-approved indications
| Indications | Juvmo (tavapadon) |
|---|---|
| “treatment of Parkinson’s disease (PD) in adults” | ✓ |
Populations in which efficacy was established
Pharmacokinetics
Table 2. Pharmacokinetic parameters
| Generic Name(s) | Bioavailability | Protein Binding | Metabolism | Excretion | Half-Life |
|---|---|---|---|---|---|
| Tavapadon | Not reported | “93% (primarily albumin)” | “Tavapadon and its major inactive metabolite M4 are primarily metabolized by CYP3A.” | “Unchanged tavapadon was a minor component in both urine and feces (less than 1%).”“Metabolite M4 accounted for less than 5% of the administered dose in both urine and feces.” | “The mean elimination half-life of tavapadon is approximately 25.5 hours.” |
Absorption, food effect, and distribution
Renal and hepatic impairment
Drug interactions
Table 3. Major drug interactions
Abbreviations: AUCτ=area under the plasma concentration-time curve over the dosing interval; AUC₀₋₂₄=area under the plasma concentration-time curve from 0 to 24 hours; BCRP=breast cancer resistance protein; Cmax=maximum plasma concentration; Cmax, daily=maximum plasma concentration on each day of the dosing interval; CYP=cytochrome P450
Adverse drug events
Table 4a. Adverse drug events reported in 3% or more of patients and at least 2% more often than with placebo in the 27-week Study 1 and Study 2 (without concomitant levodopa)
| Adverse Event | Juvmo (N = 505), % | Placebo (N = 328), % |
|---|---|---|
| Nausea | “27” | “2” |
| Headache | “17” | “5” |
| Dizziness | “14” | “4” |
| Fatigue | “10” | “3” |
| Dysgeusia | “8” | “0” |
| Vomiting | “7” | “<1” |
| Dry mouth | “5” | “<1” |
| Anxiety | “5” | “2” |
| Hypotension | “4” | “1” |
| Dyspepsia | “4” | “1” |
| Abnormal dreams | “4” | “<1” |
| Orthostatic hypotension | “4” | “<1” |
| Hallucination | “3” | “0” |
| Gastroesophageal reflux disease | “3” | “<1” |
| Constipation | “3” | “1” |
Table 4b. Adverse drug events reported in 3% or more of patients and at least 2% more often than with placebo in the 27-week Study 3 (with concomitant levodopa)
Discontinuation due to adverse reactions
Incidences reported under warnings and precautions that the tables do not carry
Dosing and administration
Table 5. Usual dosing regimens
See the current prescribing information for full details.
Titration schedule
Effectiveness
Table 6. Comparative clinical trials
Abbreviations: CI=confidence interval; LS=least squares; LSMD=least squares mean difference; MAO-B=monoamine oxidase type B; MDS-UPDRS=Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale; PD=Parkinson's disease; SE=standard error
Protocol primary endpoint of Study 1 and Study 2, which the prescribing information does not report
“The primary end point was the change from baseline to week 26 (primary efficacy time point) in the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part II (motor aspects of experiences of daily living) and part III (motor evaluation) combined score. Key secondary end points were the change from baseline to week 26 in the MDS-UPDRS part II score and the percentage of participants who had a Patient Global Impression of Change (PGIC) score of “much improved” or “very much improved” at week 26 (PGIC responders).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The change from baseline to week 26 in the MDS-UPDRS parts II and III combined score was significantly improved in both the 5-mg tavapadon group (least-squares mean [LSM] decrease of 9.7 points vs increase of 1.8 points with placebo; LSM treatment difference, −11.5; 95% CI, −13.8 to −9.2; P < .001; d = 1.14) and 15-mg tavapadon group (LSM decrease of 10.2 points vs increase of 1.8 points with placebo; LSM treatment difference, −12.1; 95% CI, −14.4 to −9.8; P < .001; d = 1.20). Improvements in MDS-UPDRS parts II and III combined scores in tavapadon-treated vs placebo-treated participants were observed as early as week 5 and continued through the end of treatment (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint of change from baseline to week 26 in the MDS-UPDRS Parts II and III combined score was significantly improved with tavapadon versus placebo (least squares mean [LSM] decrease of 10·3 [95% CI −12·2 to −8·3] points vs 1·2 [−2·9 to 0·6] points; LSM treatment difference −9·1 [95% CI −11·7 to −6·5]; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote